Last reviewed · How we verify
NCT05957341
pBFS Guided 20min Inter-session Interval rTMS Treatment for MDD
NA trial testing active rTMS: 20min inter-session interval in Moderate Depression in 50 participants. Status unknown.
30 July 2024
Quick facts
| Lead sponsor | Changping Laboratory |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 30 July 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 August 2024 |
Drugs / interventions tested
- active rTMS: 20min inter-session interval
- active rTMS: 50min inter-session interval
- sham rTMS: 20min inter-session interval
- sham rTMS: 50min inter-session interval
Conditions studied
- Moderate Depression — all drugs for Moderate Depression →
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
- Severe Depression — all drugs for Severe Depression →
Sponsor
Changping Laboratory
Who can join
Adults 18 to 65, any sex, with Moderate Depression or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to explore the efficacy and safety of rTMS therapies with different intervals between sessions for treating patients with moderate to severe depression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05957341
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Moderate Depression
Currently open trials in the same condition.
- NCT06752759 — Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting · Phase 3 · recruiting
- NCT06005103 — A Randomized Clinical Trial Comparing Active Versus Sham T-PEMF Headband Treatment for Depression · NA · recruiting
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
Other Changping Laboratory trials
Trials by the same sponsor.
- NCT06350396 — pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression · NA · recruiting
- NCT06255535 — pBFS Guided rTMS Over Cognitive Control Network for ASD · NA · recruiting
- NCT06255561 — pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression · NA · unknown
- NCT06166082 — Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression · NA · unknown
- NCT06112652 — Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05957341 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changping Laboratory
- Last refreshed: 24 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05957341.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing